Pharmagen, Inc.

PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

Independent research identified cepharanthine as a potential Hantavirus entry inhibitor, supporting evaluation of Sairiyo's patented, orally bioavailable PD-001 formulation of cepharanthine for Hantavirus Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is is pleased to announce that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 51% owned by PharmaDrug and 49% owned by PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher"), is pursuing its strategic plans to focus on the clinical development of its patented enteric-coated oral Cepharanthine ("PD-001") as a potential therapeutic candidate for Hantavirus ("HTNV").